BAJAJ BROKING

Notification
No new Notification messages
Wagons Learning IPO is Open!
Apply for the Wagons Learning IPO through UPI in just minutes.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.

532660

VIVIMEDLAB

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

VIVIMED LABS LTD. Share Price Update

As of the latest trading session, VIVIMED LABS LTD. share price is currently at ₹ 4.9, which is up by ₹ 0.00 from its previous closing. Today, the stock has fluctuated between ₹ 4.88 and ₹ 5.24. Over the past year, VIVIMED LABS LTD. has achieved a return of -52.88 %. In the last month alone, the return has been -10.42 %. Read More...

VIVIMED LABS LTD. fundamentals


  • Market cap (Cr)

  • P/E Ratio (TTM)

  • Beta

  • Book Value / share

  • Return on equity

    %

  • EPS (TTM)

  • Dividend yield

    %

  • Net profit/quarter (Cr)

info icon alternate text
  • Market cap (Cr)

    0.0

  • P/E Ratio (TTM)

    0.0

  • Beta

    0.0

  • Book Value / share

    0.0

  • Return on equity

    0.0%

  • EPS (TTM)

    0.0

  • Dividend yield

    %

  • Net profit/quarter (Cr)

    0.0

info icon alternate text

VIVIMED LABS LTD. Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars DEC 2024 (Values in Cr)
Revenue 34.23
Operating Expense 41.21
Net Profit -6.97
Net Profit Margin (%) -20.36
Earnings Per Share (EPS) -0.84
EBITDA -0.16
Effective Tax Rate (%) 0.00
Particulars SEP 2024 (Values in Cr)
Revenue 22.16
Operating Expense 27.18
Net Profit -4.99
Net Profit Margin (%) -22.51
Earnings Per Share (EPS) -0.60
EBITDA -0.76
Effective Tax Rate (%) 0.00
Particulars JUN 2024 (Values in Cr)
Revenue 24.64
Operating Expense 39.75
Net Profit -15.11
Net Profit Margin (%) -61.32
Earnings Per Share (EPS) -1.82
EBITDA -11.07
Effective Tax Rate (%) 0.00
Particulars MAR 2024 (Values in Cr)
Revenue 36.39
Operating Expense 30.65
Net Profit 5.51
Net Profit Margin (%) 15.14
Earnings Per Share (EPS) 0.66
EBITDA -21.45
Effective Tax Rate (%) 24.31
Particulars DEC 2023 (Values in Cr)
Revenue 37.14
Operating Expense 53.90
Net Profit -16.17
Net Profit Margin (%) -43.53
Earnings Per Share (EPS) -1.95
EBITDA 0.93
Effective Tax Rate (%) 3.28
Particulars MAR 2024 (Values in Cr)
Revenue 136.80
Operating Expense 184.92
Net Profit -44.38
Net Profit Margin (%) -32.44
Earnings Per Share (EPS) -5.35
EBITDA -24.07
Effective Tax Rate (%) 0.00
Particulars MAR 2023 (Values in Cr)
Revenue 176.83
Operating Expense 507.19
Net Profit -328.01
Net Profit Margin (%) -185.49
Earnings Per Share (EPS) -39.56
EBITDA -187.94
Effective Tax Rate (%) 0.64
Particulars MAR 2022 (Values in Cr)
Revenue 218.37
Operating Expense 284.56
Net Profit -67.75
Net Profit Margin (%) -31.02
Earnings Per Share (EPS) -8.17
EBITDA -7.95
Effective Tax Rate (%) -4.34
Particulars MAR 2021 (Values in Cr)
Revenue 210.05
Operating Expense 245.54
Net Profit -29.19
Net Profit Margin (%) -13.89
Earnings Per Share (EPS) -3.52
EBITDA 27.87
Effective Tax Rate (%) 0.78
Particulars MAR 2020 (Values in Cr)
Revenue 276.61
Operating Expense 303.88
Net Profit -19.17
Net Profit Margin (%) -6.93
Earnings Per Share (EPS) -2.31
EBITDA 38.83
Effective Tax Rate (%) 7.56
Particulars MAR 2024 (Values in Cr)
Book Value / Share -5.24
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.00
EBITDA Margin -11.45
Particulars MAR 2023 (Values in Cr)
Book Value / Share 0.17
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 2.25
EBITDA Margin -99.42
Particulars MAR 2022 (Values in Cr)
Book Value / Share 39.35
ROE % -18.80
ROCE % -2.15
Total Debt to Total Equity 0.95
EBITDA Margin -2.76
Particulars MAR 2021 (Values in Cr)
Book Value / Share 47.47
ROE % -16.62
ROCE % -0.93
Total Debt to Total Equity 1.07
EBITDA Margin 4.80
Particulars MAR 2020 (Values in Cr)
Book Value / Share 56.85
ROE % -20.75
ROCE % -2.55
Total Debt to Total Equity 1.11
EBITDA Margin 1.75
Particulars MAR 2024 (Values in Cr)
Book Value / Share 6.20
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 5.13
EBITDA Margin -12.96
Particulars MAR 2023 (Values in Cr)
Book Value / Share 11.50
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 1.43
EBITDA Margin -106.13
Particulars MAR 2022 (Values in Cr)
Book Value / Share 50.57
ROE % -14.96
ROCE % -2.60
Total Debt to Total Equity 0.75
EBITDA Margin -3.56
Particulars MAR 2021 (Values in Cr)
Book Value / Share 58.67
ROE % -4.65
ROCE % 1.87
Total Debt to Total Equity 0.63
EBITDA Margin 16.14
Particulars MAR 2020 (Values in Cr)
Book Value / Share 62.22
ROE % -2.34
ROCE % 2.98
Total Debt to Total Equity 0.62
EBITDA Margin 16.68
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 2.02
Total Assets 950.91
Total Liabilities 950.91
Total Equity -5.46
Share Outstanding 82913915
Price to Book Ratio 0.00
Return on Assets (%) -4.77
Return on Capital (%) -12.23
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 3.76
Total Assets 995.05
Total Liabilities 995.05
Total Equity 39.42
Share Outstanding 82913915
Price to Book Ratio 0.58
Return on Assets (%) -33.01
Return on Capital (%) -78.6
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 7.18
Total Assets 1266.01
Total Liabilities 1266.01
Total Equity 364.28
Share Outstanding 82913915
Price to Book Ratio 0.29
Return on Assets (%) -5.34
Return on Capital (%) -9.35
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 6.43
Total Assets 1289.33
Total Liabilities 1289.33
Total Equity 431.57
Share Outstanding 82913915
Price to Book Ratio 0.27
Return on Assets (%) -5.57
Return on Capital (%) -9.49
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 50.48
Total Assets 2209.61
Total Liabilities 2209.61
Total Equity 834.59
Share Outstanding 82913915
Price to Book Ratio 0.12
Return on Assets (%) -4.93
Return on Capital (%) -6.33
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 1.14
Total Assets 681.46
Total Liabilities 681.46
Total Equity 89.40
Share Outstanding 82913915
Price to Book Ratio 0.00
Return on Assets (%) -6.51
Return on Capital (%) -9.55
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 3.34
Total Assets 795.82
Total Liabilities 795.82
Total Equity 133.31
Share Outstanding 82913915
Price to Book Ratio 0.58
Return on Assets (%) -41.21
Return on Capital (%) -64.32
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 6.77
Total Assets 1071.78
Total Liabilities 1071.78
Total Equity 457.27
Share Outstanding 82913915
Price to Book Ratio 0.29
Return on Assets (%) -6.32
Return on Capital (%) -8.32
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 6.01
Total Assets 1094.83
Total Liabilities 1094.83
Total Equity 524.46
Share Outstanding 82913915
Price to Book Ratio 0.27
Return on Assets (%) -2.12
Return on Capital (%) -2.75
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 11.08
Total Assets 1067.31
Total Liabilities 1067.31
Total Equity 553.89
Share Outstanding 82913915
Price to Book Ratio 0.12
Return on Assets (%) -1.79
Return on Capital (%) -2.37
Particulars MAR 2024 (Values in Cr)
Net Income -45.82
Cash from Operations -24.08
Cash from Investing 28.28
Cash from Financing -6.03
Net change in Cash -1.73
Free Cash Flow -22.04
Particulars MAR 2023 (Values in Cr)
Net Income -330.65
Cash from Operations 35.32
Cash from Investing -4.96
Cash from Financing -33.78
Net change in Cash -3.42
Free Cash Flow 40.29
Particulars MAR 2022 (Values in Cr)
Net Income -64.27
Cash from Operations 27.54
Cash from Investing -16.41
Cash from Financing -10.37
Net change in Cash 0.75
Free Cash Flow 43.95
Particulars MAR 2021 (Values in Cr)
Net Income -75.76
Cash from Operations 542.20
Cash from Investing 404.00
Cash from Financing -1015.33
Net change in Cash -44.05
Free Cash Flow 542.20
Particulars MAR 2020 (Values in Cr)
Net Income -109.47
Cash from Operations 99.49
Cash from Investing -196.01
Cash from Financing 72.43
Net change in Cash -44.01
Free Cash Flow 212.30
Particulars MAR 2024 (Values in Cr)
Net Income -44.38
Cash from Operations -96.52
Cash from Investing 99.82
Cash from Financing -5.50
Net change in Cash -2.20
Free Cash Flow -93.99
Particulars MAR 2023 (Values in Cr)
Net Income -330.12
Cash from Operations 32.86
Cash from Investing -1.59
Cash from Financing -34.69
Net change in Cash -3.42
Free Cash Flow 34.46
Particulars MAR 2022 (Values in Cr)
Net Income -64.37
Cash from Operations 25.30
Cash from Investing -11.33
Cash from Financing -13.20
Net change in Cash 0.76
Free Cash Flow 36.64
Particulars MAR 2021 (Values in Cr)
Net Income -29.42
Cash from Operations 182.01
Cash from Investing -138.19
Cash from Financing -46.40
Net change in Cash -5.07
Free Cash Flow 246.58
Particulars MAR 2020 (Values in Cr)
Net Income -20.74
Cash from Operations 81.05
Cash from Investing 3.32
Cash from Financing -91.41
Net change in Cash -13.07
Free Cash Flow 81.05
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 36.46 19.60 1.99 279.41 34.11 / 77.70
BLISS GVS PHARMA LTD 119.00 15.60 1.24 1253.91 92.25 / 184.95
CIPLA LTD 1549.65 25.08 4.41 125155.99 1310.05 / 1702.00
FERMENTA BIOTECH LIMITED 260.70 21.60 2.64 767.27 145.00 / 449.00
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 36.46 21.96 6.19 279.41 34.11 / 77.70
AMRUTAJAN HEALTH LTD 692.80 40.61 6.72 2002.93 548.05 / 861.40
ASTRAZENECA PHARMA IND LT 8665.50 129.24 31.88 21663.75 5000.00 / 9199.00
BLISS GVS PHARMA LTD 119.00 15.45 1.22 1253.91 92.25 / 184.95

VIVIMED LABS LTD. Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
4.90 -3.92 redarrow
red-green-graph indicator
0 Bearish
0 Bullish
  • 5 Days 0.00
  • 26 Days 0.00
  • 10 Days 0.00
  • 50 Days 0.00
  • 12 Days 0.00
  • 100 Days 0.00
  • 20 Days 0.00
  • 200 Days 0.00
0.0 PIVOT

First Support

0.0

First Resistance

0.0

Second Support

0.0

Second Resistance

0.0

Third Support

0.0

Third Resistance

0.0

RSI

0.0

ADX

0.0

MACD

0.0

Williams % R

0.0

Commodity Channel Index (CCI)

0.0

Date

-

Week

0.0

Same Day

0.0

Month

0.0

1 Year

0.0

3 Year

0.0

Over 1 Month

-10.42%

down

Over 1 Year

-52.88%

down

Over 3 Months

-27.40%

down

Over 3 Years

-22.63%

down

Over 6 Months

-48.42%

down

Over 5 Years

-38.71%

down

Invest with Confidence

Left Arrow
MTF boost
Buy Now. Pay Later

Boost your capital upto 5 X

img
IPO boost
Invest in IPOs
They give good returns
img
Right Arrow

VIVIMED LABS LTD. shareholding pattern

  • Shareholding Summary

  • Historical Promotor Holding

  • Historical MF Holding

  • Historical FII Holding

Holding

Others
77.41%
Promoter Holdings
20.94%
FII
1.64%
DII
0.0%
Promoter Shares(Pledge Percentage)
37.06%
Name Shares Category
Bbr Projects Private Limited 9495504.0 (11.45%) Shareholding of Promoter and Promoter Group
Kitara Piin 1102 7766387.0 (9.37%) Public Shareholding
Varalwar Sandeep 1875647.0 (2.26%) Shareholding of Promoter and Promoter Group
Varalwar Subhash 1616200.0 (1.95%) Shareholding of Promoter and Promoter Group
William F Harvey 1369840.0 (1.65%) Public Shareholding
Sameer Mahendra Sampat 1359165.0 (1.64%) Public Shareholding
Santosh Varalwar 1300254.0 (1.57%) Shareholding of Promoter and Promoter Group
K India Opportunities Fund Limited Pcc - Cell S 1219300.0 (1.47%) Public Shareholding
Ashish Bharatkumar Shah 1174856.0 (1.42%) Public Shareholding
Manohar Rao Varalwar 1034225.0 (1.25%) Shareholding of Promoter and Promoter Group
Sheetal Varalwar 568985.0 (0.69%) Shareholding of Promoter and Promoter Group
Sujatha Varalwar 393995.0 (0.48%) Shareholding of Promoter and Promoter Group
S Raghunandan 317500.0 (0.38%) Shareholding of Promoter and Promoter Group
Madhavi Varalwar 200000.0 (0.24%) Shareholding of Promoter and Promoter Group
Mamatha Gurnukar 150000.0 (0.18%) Shareholding of Promoter and Promoter Group
Vijaykumar Varalwar 150000.0 (0.18%) Shareholding of Promoter and Promoter Group
Neelima Vijaya Varalwar 100000.0 (0.12%) Shareholding of Promoter and Promoter Group
Satish Gooty Agraharam 55635.0 (0.07%) Shareholding of Promoter and Promoter Group
Chandrashekharrao Sudigali 50095.0 (0.06%) Shareholding of Promoter and Promoter Group
Varalwar Padma 33250.0 (0.04%) Shareholding of Promoter and Promoter Group
Vithabai Varalwar 23345.0 (0.03%) Shareholding of Promoter and Promoter Group

News

Left Arrow
Right Arrow

VIVIMED LABS LTD. corporate actions

  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
[-] [-] [-] [-] [-]
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]
  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
19 Sep 2018 0.4 Final 22 Sep 2018 Equity shares
21 Sep 2017 0.4 Final 23 Sep 2017 Equity shares
24 Sep 2014 3.0 Final 26 Sep 2014 Equity shares
24 Sep 2013 3.0 Final 26 Sep 2013 Equity shares
21 Sep 2012 3.0 Final 25 Sep 2012 Equity shares
26 Sep 2011 2.0 Final 28 Sep 2011 Equity shares
09 Sep 2010 1.5 Final 14 Sep 2010 Equity shares
24 Sep 2009 1.5 Final 28 Sep 2009 Equity shares
22 Sep 2008 1.0 Final 24 Sep 2008 Equity shares
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
06 Apr 2016 10.0 2.0 08 Apr 2016

VIVIMED LABS LTD. Share Price

Vivimed Labs Limited was originally incorporated on September 22, 1988 as a private limited company in the name of Emgi Pharmaceuticals & Chemicals Pvt Ltd. On April 21, 1994, the company got converted into a public limited company and the name was changed to Emgi Pharmaceuticals & Chemicals Ltd and thereafter, the Company name was finally changed to Vivimed Labs Limited on April 22, 1997.

The Company is engaged in manufacturing of Specialty Chemicals (mainly used in Personal Care and Cosmetic Industry), Pharmaceuticals, API's and Formulations. The company has strong presence in the areas of Health & Personal Care, Contract Research and Manufacturing. The company has four subsidiary companies, namely Creative Health Care Pvt Ltd, Vivimed Holdings Ltd (Hong Kong), Vivimed Labs Europe Ltd (UK) and Vivimed Labs USA Inc.

The company operates in two different industry segments, namely Specialty Chemicals and Pharma Manufacturing. The specialty chemicals segment manufactures a range of products active ingredients for home and personal care and personal hygiene products. Pharmaceutical segment is engaged in contract manufacturing and job works.

The company's portfolio has a range of specialty chemicals (active ingredients) supplied to manufacturers of beauty care products like hair care, skin care, sun care and oral care products, industrial care products, such as anti-microbial, anti-fouling agents and biocides and health care products like pharmaceutical finished drug forms for cancer, tuberculosis.

The company's manufacturing capacities are broadly divided into: cGMP manufacturing facility located at Bidar in Karnataka State of India- capacity 250 kl per day. A second cGMP plant, located at Bonthapalli, Hyderabad, India- capacity 400 kl per day. Three Pharmaceutical Finished Dose Plants: at Jeedimetla, Hyderabad, Kashipur, Uttarakhand, Haridwar, Uttarakhand: with complete lines of finished dosage pharmaceutical products.

The company was originally promoted by A M Rao. On Rao's accidental death the company was put for a sale. In the year 1989, Santosh Varalwar and Subhash Varalwar acquired Emgi Pharmaceuticals and Chemicals Ltd. In the year 1990, the company commenced production of Non-Steroidal Anti-Inflammatory Drug (NSAID), 'Ibuprofen'.

In the year 1994, the company diversified and expanded the product mix by adding other APIs viz. Chlorzoxazone (Skeletal disorders), Nalidixic Acid (Anti-diarrheas) and Flucanazole (Anti-fungal). In the year 1995, the company diversified into specialty chemicals by production of Triclosan. In the year 1996, the company's R&D was commenced with facilities having an integrated instrumentation for organic synthesis, Microbiology and pre-formulation studies. In April 22, 1997, the company changed their name from Emgi Pharmaceuticals & Chemicals Ltd to Vivimed Labs Ltd.

During the year 1998-99, the company expanded the customer base of Triclosan to UK, France, Germany as well as domestic market. In the year 2002, they developed Anti-fungal for usage in High-end cosmetic and pre-formulation blends. In the year 2003, they signed Confidential Sale Agreement with HLL for R&D, scaling up and commercialization of product coded as A123.

In the year 2004, the company introduced new products for anti-dandruff and skin care application. They increased the production capacity of Triclosan from 225 MTPA to 480 MTPA. They developed novel synthetic process to manufacture a premium Anti-oxidant and Anti-cancer molecule branded as Vintox. Also, they established manufacturing facilities of Sterile and Small Volume Parentals at Haridwar in Uttarakhand.

In the year 2005, the company came out with the public issue and their shares were listed at BSE and NSE. They established a new production facility at Hyderabad for specialty chemicals. They received State Award for Excellence in Exports (SSI GOLD) from Karnataka State Government for excellence in exports.

In the year 2006, the company established additional Pharmaceuticals manufacturing facility at Kashipur in Uttarakhand. In May 2008, the company acquired UK-based James Robinson Ltd (now known as Vivimed Labs Europe Ltd) in order to increase their global presence in the specialty chemicals market.

During the year 2008-09, the company received new product approvals from several existing clients. They made tie ups with L'oreal and P & G for innovative research on new molecules. The company acquired 80 acres of land at Vishakhapatnam to set up a Greenfield Project to meet growing market demand in Chemical Sector and for Diversification.

During the year, the company's pharma division developed Trimedronate Capsules 250 mg, a cardio- regulator formulation for Russia and CIS Markets and registered the API and formulations in Russia and Ukraine. Also, the company registered two formulations for the Ukranian market, namely Bolarex and Rapidact.

During the year 2009-10, the company acquired US-based Harmet International Inc. (now known as Vivimed Labs USA, Inc), as a part of their strategic intent to increase the company's presence and reach within the NAFTA region. Also, they commissioned their new R&D facility at Mallapur.

In June 2010, International Specialty Products (ISP), a New Jersey - based chemical supplier has forged a manufacturing alliance with the company for production of UV absorbers. The manufacturing alliance will allow the two companies to jointly market specific products used in sprays and lotions that include UVA and UVB protective properties.

In December 2010, the company commenced commercial production at their new facility for manufacturing of sunscreens set up at Bidar, Karnataka. Also, the company has increased capacities for other ingredients in Oral care/ Hair care segments.

In 2011, the Company acquired Uquifa, a leading global API manufacturer based in Spain and Mexico, in November 2011; it acquired Klar Sehen Pvt. Ltd, a niche ophthalmic formulations company based in India, in October 2011 and further acquired Octtantis Nobel Labs Pvt. Ltd, a branded formulations marketing company, in September 2011.

In 2013, it commissioned Bidar block for Pharma Intermediates; upgraded Jeedimetla facility to PICS standards; established API R&D with 65 scientists and formulations R&D with 45 scientists.

The Company in 2014 acquired seven domestic Formulation brand. It introduced 5 new products in the Personal Care segment (especially the Sun Care and Hair Care segments). It launched a substitute for Triclosan . It launched new products and brands in the pain management, anti-spasmodic and ophthalmology segment.

In 2015, the Company opened doors for generics in regulated markets. In July 2016, the Company transferred and sold its entire product portfolio along with their associated trademarks under the aegis of its wholly-owned subsidiary Klar Sehen Private Limited to Ordain Healthcare Global Private Limited, which is a subsidiary of Spainbased Chemo Espana S.A. It launched a new product called MBB in the hair care category.

In 2018, the Company, through its Spanish subsidiary, Vivimed Spain, acquired Soneas, a Hungary-based CDMO player and manufacturer of fine chemicals for pharmaceutical and other sectors. It raised $50 million from Orbimed Asia III Mauritius Limited to increase capacity and drive higher organic growth of the Company's API business. It formed a distribution agreement with Alter Ego LLC for distributing its products in Ukraine, Russia and other CIS regions.

In 2023, the Company developed complex products like Sitagliptin + Metformin IR Tablets/ ER Tablets, Empagliflozin Tablets; developed an Antidiabetic product basket for Canadian and EU clients; started commercial supplies of products like Rivaroxaban Tablets and Dalfampiridine Tablets; completed and started New parenteral R&D Analytical Section.

Parent organization Indian Private
NSE symbol VIVIMEDLAB
Founded 1988
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Share Price of Vivimed Labs Ltd?

Answer Field

The share price of Vivimed Labs Ltd for NSE is ₹ 4.95 and for BSE is ₹ 4.90.

What is the Market Cap of Vivimed Labs Ltd?

Answer Field

The market cap of Vivimed Labs Ltd for NSE is ₹ 0.0 Cr. and for BSE is ₹ 0.0 Cr. as of now.

What is the 52 Week High and Low of Vivimed Labs Ltd?

Answer Field

The 52 Week High and Low of Vivimed Labs Ltd for NSE is ₹ 5.25 and ₹ 0.00 and for BSE is ₹ 5.24 and ₹ 0.00.

How to Buy Vivimed Labs Ltd share?

Answer Field

You can trade in Vivimed Labs Ltd shares with Bajaj Broking by opening a Demat Account.

What is 1 year return for Vivimed Labs Ltd?

Answer Field

The 1 year returns on the stock has been -52.88%.

What is the Current Share Price of Vivimed Labs Ltd?

Answer Field

Vivimed Labs Ltd share price is for NSE ₹ 4.95 & for BSE ₹ 4.90 as on Jul 31 2023 12:00 AM.

What is the Market Cap of Vivimed Labs Ltd Share?

Answer Field

The market cap of Vivimed Labs Ltd for NSE ₹ 0.0 & for BSE ₹ 0.0 as on Jul 31 2023 12:00 AM.

What is the P/E Ratio of Vivimed Labs Ltd Share?

Answer Field

As on Jul 31 2023 12:00 AM the price-to-earnings (PE) ratio for Vivimed Labs Ltd share is 0.0.

What is the PB ratio of Vivimed Labs Ltd Share?

Answer Field

As on Jul 31 2023 12:00 AM, the price-to-book (PB) ratio for Vivimed Labs Ltd share is 0.0.

How to Buy Vivimed Labs Ltd Share?

Answer Field

You can trade in Vivimed Labs Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Vivimed Labs Ltd Share on Bajaj Broking App?

Answer Field

To buy Vivimed Labs Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Vivimed Labs Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|